The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Advice for physicians on the treatment of patients with multiple myeloma
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, Miami, FL, shares advice for community physicians regarding the treatment of multiple myeloma (MM). In such a rapidly evolving field, physicians need to stay updated to ensure the best care for their patients. Additionally, with more complex new drugs, it is important to know what side effects to look out for, such as cytokine release syndrome (CRS) or immunosuppression, in order to manage them in a timely manner and avoid causing harm. Dr Landgren highlights that more work needs to be conducted to identify optimal administration schedules to balance safety and efficacy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Honoraria: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on an entity’s Board of Directors or advisory committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on independent data monitoring committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex.
